Phase I trial of escalating-dose cisplatin with 5-fluorouracil and concurrent radiotherapy in Chinese patients with esophageal cancer

Qiang Lin, Xian Shu Gao, Xue Ying Qiao, Zhi Guo Zhou, Ping Zhang, Kun Chen, Yan Nan Zhao, Jun-Ichi Asaumi

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

We defined the maximum-tolerated dose (MTD) of chemoradiotherapy (cisplatin (CDDP) with 5-fluorouracil (5-FU) and concurrent chemoradiotherapy) for Chinese patients with esophageal cancer. Twenty-one previously untreated patients with primary esophageal cancer were entered into this study. Escalating doses of CDDP with 5-FU were administered in a modified Fibonacci sequence, with concurrent conventional fractionation radiotherapy (CFR) of 60 Gy or 50 Gy. The starting doses were CDDP 37.5 mg/m2 on day 1, and 5-FU 500 mg/m2 on days 1-5, respectively. The regimen was repeated 4 times every 28 days. If no dose-limiting toxicity (DLT) was observed, the next dose level was applied. The procedures were repeated until DLT appeared. The MTD was declared to be 1 dose level below the level at which DLT appeared. DLT was grade 3 radiation-induced esophagitis at a dose level of CDDP 60 mg/m2 with 5-FU 700 mg/m 2 and concurrent 60 Gy CFR. MTD was defined as CDDP 52.5 mg/m 2 with 5-FU 700 mg/m2 and concurrent 50 Gy CFR. The MTD of CDDP with 5-FU and in concurrent chemoradiotherapy for Chinese patients with esophageal cancer is CDDP 52.5 mg/m2 on day 1 and 5FU 700 mg/m 2 on days 1-5, repeated 4 times every 28 days, and concurrent 50 Gy CFR. Further evaluation of this regimen in a prospective phase II trial is ongoing. Copyright

Original languageEnglish
Pages (from-to)37-44
Number of pages8
JournalActa Medica Okayama
Volume62
Issue number1
Publication statusPublished - Feb 2008

Fingerprint

Radiotherapy
Esophageal Neoplasms
Fluorouracil
Cisplatin
Dosimetry
Chemoradiotherapy
Maximum Tolerated Dose
Fractionation
Toxicity
Esophagitis
Radiation

Keywords

  • 5-fluorouracil
  • Cisplatin
  • Concurrent chemoradiotherapy
  • Dose escalation
  • Esophageal neoplasm

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Phase I trial of escalating-dose cisplatin with 5-fluorouracil and concurrent radiotherapy in Chinese patients with esophageal cancer. / Lin, Qiang; Gao, Xian Shu; Qiao, Xue Ying; Zhou, Zhi Guo; Zhang, Ping; Chen, Kun; Zhao, Yan Nan; Asaumi, Jun-Ichi.

In: Acta Medica Okayama, Vol. 62, No. 1, 02.2008, p. 37-44.

Research output: Contribution to journalArticle

Lin, Qiang ; Gao, Xian Shu ; Qiao, Xue Ying ; Zhou, Zhi Guo ; Zhang, Ping ; Chen, Kun ; Zhao, Yan Nan ; Asaumi, Jun-Ichi. / Phase I trial of escalating-dose cisplatin with 5-fluorouracil and concurrent radiotherapy in Chinese patients with esophageal cancer. In: Acta Medica Okayama. 2008 ; Vol. 62, No. 1. pp. 37-44.
@article{9e9c19c3ecb946ea809ce9f4b745f796,
title = "Phase I trial of escalating-dose cisplatin with 5-fluorouracil and concurrent radiotherapy in Chinese patients with esophageal cancer",
abstract = "We defined the maximum-tolerated dose (MTD) of chemoradiotherapy (cisplatin (CDDP) with 5-fluorouracil (5-FU) and concurrent chemoradiotherapy) for Chinese patients with esophageal cancer. Twenty-one previously untreated patients with primary esophageal cancer were entered into this study. Escalating doses of CDDP with 5-FU were administered in a modified Fibonacci sequence, with concurrent conventional fractionation radiotherapy (CFR) of 60 Gy or 50 Gy. The starting doses were CDDP 37.5 mg/m2 on day 1, and 5-FU 500 mg/m2 on days 1-5, respectively. The regimen was repeated 4 times every 28 days. If no dose-limiting toxicity (DLT) was observed, the next dose level was applied. The procedures were repeated until DLT appeared. The MTD was declared to be 1 dose level below the level at which DLT appeared. DLT was grade 3 radiation-induced esophagitis at a dose level of CDDP 60 mg/m2 with 5-FU 700 mg/m 2 and concurrent 60 Gy CFR. MTD was defined as CDDP 52.5 mg/m 2 with 5-FU 700 mg/m2 and concurrent 50 Gy CFR. The MTD of CDDP with 5-FU and in concurrent chemoradiotherapy for Chinese patients with esophageal cancer is CDDP 52.5 mg/m2 on day 1 and 5FU 700 mg/m 2 on days 1-5, repeated 4 times every 28 days, and concurrent 50 Gy CFR. Further evaluation of this regimen in a prospective phase II trial is ongoing. Copyright",
keywords = "5-fluorouracil, Cisplatin, Concurrent chemoradiotherapy, Dose escalation, Esophageal neoplasm",
author = "Qiang Lin and Gao, {Xian Shu} and Qiao, {Xue Ying} and Zhou, {Zhi Guo} and Ping Zhang and Kun Chen and Zhao, {Yan Nan} and Jun-Ichi Asaumi",
year = "2008",
month = "2",
language = "English",
volume = "62",
pages = "37--44",
journal = "Acta Medica Okayama",
issn = "0386-300X",
publisher = "Okayama University",
number = "1",

}

TY - JOUR

T1 - Phase I trial of escalating-dose cisplatin with 5-fluorouracil and concurrent radiotherapy in Chinese patients with esophageal cancer

AU - Lin, Qiang

AU - Gao, Xian Shu

AU - Qiao, Xue Ying

AU - Zhou, Zhi Guo

AU - Zhang, Ping

AU - Chen, Kun

AU - Zhao, Yan Nan

AU - Asaumi, Jun-Ichi

PY - 2008/2

Y1 - 2008/2

N2 - We defined the maximum-tolerated dose (MTD) of chemoradiotherapy (cisplatin (CDDP) with 5-fluorouracil (5-FU) and concurrent chemoradiotherapy) for Chinese patients with esophageal cancer. Twenty-one previously untreated patients with primary esophageal cancer were entered into this study. Escalating doses of CDDP with 5-FU were administered in a modified Fibonacci sequence, with concurrent conventional fractionation radiotherapy (CFR) of 60 Gy or 50 Gy. The starting doses were CDDP 37.5 mg/m2 on day 1, and 5-FU 500 mg/m2 on days 1-5, respectively. The regimen was repeated 4 times every 28 days. If no dose-limiting toxicity (DLT) was observed, the next dose level was applied. The procedures were repeated until DLT appeared. The MTD was declared to be 1 dose level below the level at which DLT appeared. DLT was grade 3 radiation-induced esophagitis at a dose level of CDDP 60 mg/m2 with 5-FU 700 mg/m 2 and concurrent 60 Gy CFR. MTD was defined as CDDP 52.5 mg/m 2 with 5-FU 700 mg/m2 and concurrent 50 Gy CFR. The MTD of CDDP with 5-FU and in concurrent chemoradiotherapy for Chinese patients with esophageal cancer is CDDP 52.5 mg/m2 on day 1 and 5FU 700 mg/m 2 on days 1-5, repeated 4 times every 28 days, and concurrent 50 Gy CFR. Further evaluation of this regimen in a prospective phase II trial is ongoing. Copyright

AB - We defined the maximum-tolerated dose (MTD) of chemoradiotherapy (cisplatin (CDDP) with 5-fluorouracil (5-FU) and concurrent chemoradiotherapy) for Chinese patients with esophageal cancer. Twenty-one previously untreated patients with primary esophageal cancer were entered into this study. Escalating doses of CDDP with 5-FU were administered in a modified Fibonacci sequence, with concurrent conventional fractionation radiotherapy (CFR) of 60 Gy or 50 Gy. The starting doses were CDDP 37.5 mg/m2 on day 1, and 5-FU 500 mg/m2 on days 1-5, respectively. The regimen was repeated 4 times every 28 days. If no dose-limiting toxicity (DLT) was observed, the next dose level was applied. The procedures were repeated until DLT appeared. The MTD was declared to be 1 dose level below the level at which DLT appeared. DLT was grade 3 radiation-induced esophagitis at a dose level of CDDP 60 mg/m2 with 5-FU 700 mg/m 2 and concurrent 60 Gy CFR. MTD was defined as CDDP 52.5 mg/m 2 with 5-FU 700 mg/m2 and concurrent 50 Gy CFR. The MTD of CDDP with 5-FU and in concurrent chemoradiotherapy for Chinese patients with esophageal cancer is CDDP 52.5 mg/m2 on day 1 and 5FU 700 mg/m 2 on days 1-5, repeated 4 times every 28 days, and concurrent 50 Gy CFR. Further evaluation of this regimen in a prospective phase II trial is ongoing. Copyright

KW - 5-fluorouracil

KW - Cisplatin

KW - Concurrent chemoradiotherapy

KW - Dose escalation

KW - Esophageal neoplasm

UR - http://www.scopus.com/inward/record.url?scp=41549114727&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=41549114727&partnerID=8YFLogxK

M3 - Article

C2 - 18323870

AN - SCOPUS:41549114727

VL - 62

SP - 37

EP - 44

JO - Acta Medica Okayama

JF - Acta Medica Okayama

SN - 0386-300X

IS - 1

ER -